List prices for GLP-1 medications such as Wegovy and Ozempic will drop by as much as 50 percent next year, pharmaceutical company Novo Nordisk announced.
Beginning Jan. 1, the U.S. list price for Wegovy, Ozempic and Rybelsus — all semaglutide-based treatments — will be set at $675.
The move marks a 50 percent reduction for both oral and injectable versions of Wegovy, which currently carry a list price of $1,349.02. Ozempic and Rybelsus, now priced at $1,027.51, will see a 34 percent cut.
“Lowering the list price of Wegovy® and Ozempic® is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,” said Jamey Millar, executive vice president of Novo Nordisk’s U.S. operations, in a statement.
Amid surging demand, Novo has been exploring ways to expand access to its blockbuster semaglutide products. The company has launched direct-to-consumer platforms and partnered with telemedicine providers to offer lower-cost options, including versions without the autoinjector device.
Federal pressure has also played a role in the broader pricing landscape. The Centers for Medicare and Medicaid Services selected semaglutide for Medicare price negotiations last year. In November, CMS announced it had secured a 71 percent discount on a 30-day supply of the drug for Medicare beneficiaries, reducing the price from $959 to $274. Those negotiated rates are scheduled to take effect in 2027.
The Trump administration also encouraged drugmakers, including Novo Nordisk, to enter “most favored nation” pricing agreements. Under those deals, manufacturers agreed to offer GLP-1 injectables at a starting monthly price of $245 for Medicare and Medicaid enrollees.
Earlier this month, Ozempic and Wegovy were among the first medications listed on the newly launched TrumpRx platform, which advertises coupons offering discounts of roughly 80 percent off list prices.
A Novo Nordisk spokesperson told The Hill that the newly announced price reductions are not connected to the company’s most favored nation agreement with the administration.
